EXECUTIVE DIRECTORS

Ms. LI, Kei Ling, aged 58, is an Executive Director and the Chairman of the Company, and one of the founders of the Group. Ms. Li joined the Group in December 1995 and was appointed to the Board in October 2002. Ms. Li is also the Chairman of Dawnrays International Co., Ltd., Suzhou Dawnrays Pharmaceutical Co., Ltd., Shanghai Dawnrays Chemical Co., Ltd., Suzhou Dawnrays Chemical Co., Ltd. and Dawnrays Pharma (Hong Kong) Ltd., which are all subsidiaries of the Company. She is the Chairman of the Remuneration Committee and Nomination Committee. Ms. Li has over twenty years of experience in corporate management, strategic planning, business operations and finance, in particular for pharmaceutical enterprises in the PRC. She is responsible for supervising the strategic management decisions to ensure disciplined corporate governance and business policies, and executing the overall developmental strategies of the Group.

Mr. HUNG, Yung Lai, aged 62, is an Executive Director and one of the founders of the Group. Mr. Hung joined the Group in December 1995 and was appointed to the Board in October 2002. Mr. Hung also holds directorship in Dawnrays International Co., Ltd., Suzhou Dawnrays Pharmaceutical Co., Ltd., Shanghai Dawnrays Chemical Co., Ltd., and Suzhou Dawnrays Chemical Co., Ltd., which are all subsidiaries of the Company. Mr. Hung holds a degree from Shanghai Conservatory of Music (上海音樂學院). He has over twenty years of experience in corporate management and corporate development, and participated in founding and managing of pharmaceutical and high-tech enterprises. Mr. Hung is an executive director and the chairman of Sing Lee Software (Group) Limited, a company listed on the Growth Enterprise Market of the Stock Exchange.

Mr. LI, Tung Ming, aged 58, is an Executive Director of the Company. Mr. Li joined the Group in April 2000 and was appointed to the Board in January 2004. Mr. Li also holds directorship in Suzhou Dawnrays Pharmaceutical Co., Ltd., Shanghai Dawnrays Chemical Co., Ltd. and Suzhou Dawnrays Chemical Co., Ltd., which are all subsidiaries of the Company. Mr. Li has over twenty years of experience in the pharmaceutical industry in the PRC, and began his career in product development, promotion, sales and corporate management in the pharmaceutical market in the PRC in 1980. Mr. Li has participated in new products development and is responsible for liaison with the Group's academic network of medical experts and academic advisers.

Mr. GAO, Yi, aged 53, is an Executive Director and the Chief Executive Officer of the Company. He joined the Group in July 2003 and was the Executive Vice President of the Group. Mr. Gao was appointed to the Board in January 2007. He also holds directorship in Suzhou Dawnrays Pharmaceutical Co., Ltd., Shanghai Dawnrays Chemical Co., Ltd., and Suzhou Dawnrays Chemical Co., Ltd., which are all subsidiaries of the Company. Mr. Gao is responsible for the daily business operations and management of the Group. From 1994 to 2003, Mr. Gao was the deputy general manager and general manager of Hebei Union Pharmaceutical Co., Ltd. and Zhuhai Economic Zone Li Kang Pharmaceuticals Company Limited respectively each for five years.

NON-EXECUTIVE DIRECTOR

Mr. LEUNG, Hong Man, aged 32, is a Non-executive Director of the Company. He joined the Group and was appointed to the Board in November 2005. Mr. Leung has started his business career in knitting machinery since 1993. He has over 10 years' experience in sales and management positions and over 6 years' experience in investment management. Mr. Leung currently is the shareholder and the director of Toyo International Investment Ltd., of which has been one of the substantial shareholders (as required to be disclosed under Part XV of the Securities and Futures Ordinance) of the Company since September 2005.

執行董事

李其玲女士,58歲,本公司執行董事兼主席及本集團創辦人之 一。李女士於一九九五年十二月加盟本集團並於二零零二年十 月被委任為董事。李女士亦是本公司之附屬公司包括東瑞國際 有限公司、蘇州東瑞製藥有限公司、上海東瑞化工有限公司、 蘇州東瑞化工有限公司及東瑞葯業(香港)有限公司主席,彼也 是薪酬委員會及提名委員會主席。李女士於策略規劃、業務運 作及財務等企業管理方面,尤其在中國製藥企業的上述有關方 面,擁有逾二十年經驗。彼負責決策體系的經營管理,確保制 定良好的企業管治條規和營業方針,及制定企業整體發展策略 之工作。

熊融禮先生,62歲,本集團執行董事兼創辦人之一。熊先生於 一九九五年十二月加盟本集團並於二零零二年十月被委任為董 事。熊先生亦於本公司之附屬公司包括東瑞國際有限公司、蘇 州東瑞製藥有限公司、上海東瑞化工有限公司和蘇州東瑞化工 有限公司擔任董事職務。熊先生持有上海音樂學院的學位。彼 於企業管理與公司發展方面擁有逾二十年經驗,並曾創立及管 理製藥及高科技企業。熊先生是聯交所創業板上市公司新利軟 件(集團)股份有限公司的執行董事兼主席。

李東明先生,58歲,本公司執行董事。李先生於二零零零年四 月加盟本集團,及於二零零四年一月被委任為董事。李先生亦 於本公司之附屬公司包括蘇州東瑞製藥有限公司、上海東瑞化 工有限公司和蘇州東瑞化工有限公司擔任董事職務。李先生於 一九八零年開始從事中國醫藥市場的產品開發、推廣、銷售及 企業的管理工作,擁有逾二十年經驗。李先生參與本集團新產 品的開發及負責本集團醫學專家和醫葯學術顧問之學術網路聯 繫工作。

高毅先生,53歲,本公司執行董事兼總裁,彼於二零零三年七 月加盟本集團擔任本集團常務副總裁,並於二零零七年一月被 委任為董事。彼亦於本公司之附屬公司包括蘇州東瑞製藥有限 公司、上海東瑞化工有限公司和蘇州東瑞化工有限公司擔任董 事職務。高先生負責本集團日常業務的營運及管理工作。高先 生於一九九四年至二零零三年期間分別在河北聯合製藥有限公 司和珠海經濟特區麗康醫藥有限公司任副總經理及總經理各五 年。

非執行董事

梁康民先生,32歲,本公司非執行董事,彼於二零零五年十一 月加入本集團及被委任為董事。梁先生自一九九三年開展針織 機械事業,在銷售及管理工作方面累積超過十年經驗,以及逾 六年的投資經驗。梁先生現時為東海國際投資有限公司(自二 零零五年九月起成為本公司根據證券及期貨條例第XV部需要披 露的主要股東之一)的股東及董事。

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. PAN, Xue Tian, aged 70, is an Independent Non-executive Director of the Company. Mr. Pan joined the Group in June 2003. He is a member of the Remuneration Committee, the Audit Committee and the Nomination Committee of the Company. Mr. Pan is the vice president and secretary general of 中國醫院協會 (Chinese Hospital Association) and the executive vice president of 中國保健協會 (China Health Care Association). Mr. Pan has extensive experience in drug administration and supervision, medical hygiene and hospital management, and has assumed various senior management positions in the Ministry of Health of the PRC. He graduated from the medicine faculty of 中國大連醫學院 (Dalian Medical University of the PRC).

Mr. CHOI, Tat Ying Jacky, aged 38, is an Independent Non-executive Director of the Company. Mr. Choi joined the Group in September 2004. He is a member of the Remuneration Committee, the Audit Committee and the Nomination Committee of the Company. Mr. Choi has extensive experience in financial and treasury management, corporate finance, investment and audit. He earned his Bachelor degree of Business Administration from Hong Kong Baptist University with a first class honours in 1990. Mr. Choi is a practising member of the Hong Kong Institute of Certified Public Accountants and currently serving as the chief financial officer of AlG Finance (Hong Kong) Ltd., which he has served as director since 20 March 2004. He is also an independent non-executive director of both Norstar Founders Group Ltd., a company listed on the Main Board of the Stock Exchange, and Enzyme Engineering Corporation, a private company.

Mr. SIK Siu Kwan, aged 39, is an Independent Non-executive Director of the Company. Mr. Sik joined the Group in January 2007. He is also the Chairman of the Audit Committee, a member of the Remuneration Committee and the Nomination Committee of the Company respectively. Mr. Sik has more than fifteen years of experience in investment banking and finance. He has held senior positions with a number of major international investment banking operation of a state-owned PRC bank, responsible for business development and regional business operations. He achieved first class honours in his Bachelor's degree in engineering from Oxford University in 1989 and is a member of The Institute of Chartered Accountants in England and Wales. He is an independent non-executive director of China Glass Holdings Limited and Neolink Cyber Technology (Holding) Limited respectively. All these two companies are listed on the Stock Exchange.

STRATEGIC ADVISER

Mr. XU, Kehan, aged 34, is a Strategic Adviser of the Company. He joined the Group in November 2003 and was an Executive Director and the Finance Director of the Company between March 2004 and 18 March 2007. Mr. Xu holds directorship in Dawnrays Pharma (Hong Kong) Ltd., a subsidiary of the Company. Mr. Xu is responsible for advising corporate investment policies and conducting strategic research for the Group. He holds a Master of Business Administration from the University of Miami, USA with specialization in investment. Mr. Xu is currently a doctoral candidate specializing in strategic management and international business/ policies.

獨立非執行董事

潘學田先生,70歲,本公司獨立非執行董事。潘先生於二零零 三年六月加盟本集團。彼現為本公司薪酬委員會、審核委員會 及提名委員會成員。潘先生為中國醫院協會副會長兼秘書長及 中國保健協會的常務副理事長。潘先生在藥物管理及監管、醫 療衛生及醫院管理方面擁有豐富經驗。潘先生曾於中國衛生部 擔任多個高級管理層職位。潘先生畢業於中國大連醫學院醫學 系。

蔡達英先生,38歲,本公司獨立非執行董事,蔡先生於二零零 四年九月加盟本集團。彼現為本公司薪酬委員會、審核委員會 及提名委員會成員。蔡先生於財務及財資管理、公司融資、投 資及核數方面擁有豐富經驗。蔡先生於一九九零年在香港浸會 大學取得工商管理學士一級榮譽學位。蔡先生是香港會計師公 會執業會員,現為美國國際信貸(香港)有限公司財務總監,並 於二零零四年三月二十日起擔任該公司董事。蔡先生亦是聯交 所主板上市公司北泰創業集團有限公司和一私人公司Enzyme Engineering Corporation的獨立非執行董事。

薛兆坤先生,39歲,本公司獨立非執行董事,薛先生於二零零 七年一月加盟本集團。彼現分別為本公司審核委員會的主席、 薪酬委員會及提名委員會的成員。薛先生擁有逾十五年投資銀 行及財務經驗。彼曾在多間大型國際投資銀行及在一間中國國 有銀行之核心證券及投資銀行營運之香港企業擔任高級職位, 負責業務發展及地區業務營運。彼於一九八九年獲牛津大學工 程系一級榮譽學士學位。彼亦為英格蘭及威爾斯特許會計師公 會會員。彼現為中國玻璃控股有限公司及優能數碼科技(控股) 有限公司之獨立非執行董事,該兩間公司均於聯交所上市。

策略顧問

許克寒先生,34歲,本公司策略顧問。彼於二零零三年十一月 加盟本集團,並曾於二零零四年三月至二零零七年三月十八日 期間擔任本公司執行董事及財務董事。許先生為本公司之附屬 公司-東瑞葯業(控股)有限公司擔任董事職務。許先生負責為 本集團提供企業投資政策建議及進行策略研究工作。彼持有美 國邁阿密大學工商管理碩士學位,專業方向為投資。許先生現 時為博士候選人,研究方向為策略管理及國際商業/政策。

ACADEMIC ADVISERS

Mr. ZHONG, Nan Shan, was invited to join our Group as a Senior Academic Adviser in April 2004. He graduated from the 北京大學醫學部 (Beijing Medical University), and pursued his studies in the Respiratory Medicine Unit of the Royal Infirmary, University of Edinburgh and the Department of Respiratory Medicine of the St. Bartholomew's Hospital, University of London. He is currently the academician of the Department of Medicine of The Chinese Academy of Engineering, the president of Chinese Medical Association, the professor of medicine in Guangzhou Medical College, the president of Guangzhou Association of Science and Technology and the director of Guangzhou Institute of Respiratory Disease. He has been a medical adviser of the World Health Organisation Advisory Panel on Chromic Respiratory Disease since 2000. He has written 4 books and published over 120 papers in the last decade. After the battle of Severe Acute Respiratory Syndrome ("SARS"), he was invited to be the lecturer in the annual meeting of American Thoracic Society – "Management of SARS in China" in Seattle, the United States.

Mr. MEI, Hua, was invited to join our Group as a Senior Academic Adviser in April 2004. He graduated from the 廣州華南醫學院(Guangzhou South China Medical College) and was qualified as the specialist in urology from 北京醫學院附屬第一醫院 (The First Affiliated Hospital of Beijing Medical University) and Massachusetts General Hospital, USA. He has been the adviser and professor of 中山大學附屬第一醫院泌尿外科 (Department of Urology of The First Affiliated Hospital of Sun Yatsen University) since 1980 and a director of 深圳中山泌尿外科醫院(Department of Urology of Shenzhen Sun Yat-sen Hospital) since 1986. Since 1991, he has been the adviser for doctoral candidates in the First Affiliated Hospital of Sun Yat-sen University, the committee vice president of 中華醫學會泌尿外科學會 (The Urological Association) of Asia and American Urological Association. Mr. Mei has also written 3 books about urology and surgery.

Ms. LIU, Li Sheng, was invited to join our Group as a Senior Academic Adviser in May 2005. She obtained a Bachelor degree of Science in Biology from Yenching University, Beijing in 1950, and a Doctor of Medicine from Peking Union Medical College, Beijing in 1954. In 1981, she obtained a Postdoctoral degree from the Cardiovascular Research and Training Centre, University of Alabama at Birmingham. She is currently the professor of medicine in Fu Wai Hospital, Chinese Academy of Medical Sciences in Beijing, the director of Clinical Trials and Research Centre, Chinese Hypertension League in Beijing, the vice director of the National Center for Cardiovascular Disease Control & Research in China and the president of Asian Pacific Society of Hypertension. She has been the president and the honorary president of the Chinese Society of Cardiology since 1988 and the president of the Chinese Hypertension League since 1989. Ms. Liu has also been the vice president of the World Hypertension League and the co-chairperson of the Scientific Sterring Committee of Global Health Forum Cardiovascular Disease in Developing Countries, World Health Organization since 1999. In 2006, Ms. Liu has been elected to be the president of the World Hypertension League. She has been the chief editor of the Chinese Journal of Hypertension and the members of a number of editorial boards of journals in cardiology and hypertension.

醫葯學術顧問

鍾南山先生,於二零零四年四月接受邀請成為本集團高級醫藥 學術顧問。鍾先生畢業於北京大學醫學部,曾赴英國愛丁堡皇 家呼吸系統醫學院及英國倫敦大學St. Bartholomew's Hospital 呼吸系統醫學院進修。鍾南山先生現時為中國工程院院士、中 華醫學會會長、廣州醫學院內科教授及廣州市科學技術協會的 主席。由二零零零年起,鍾先生已成為聯合國世界衛生組織呼 吸疾病醫學顧問,亦是廣州呼吸疾病研究所所長。過去十年 來,鍾先生一共撰寫了四本著作及超過一百二十份的有關醫學 論文。沙士一疫後,鍾先生被邀請到美國西雅圖,為美國胸肺 醫學會年會上的客席講師,發表「中國沙士一疫的管理」。

梅購先生,於二零零四年四月接受邀請成為本集團高級醫藥學 術顧問。梅驊先生畢業於廣州華南醫學院,亦取得北京醫學院 附屬第一醫院及美國麻省總醫院泌尿外科專科資格。梅先生於 一九八零年至今為中山大學附屬第一醫院泌尿外科主任導師 及教授,由一九八六年至今為深圳中山泌尿外科醫院院長。 一九九一年開始,梅先生於中山大學附屬第一醫院任博士生導 師,並擔任中華醫學會泌尿外科學會副主任委員、亞洲泌尿外 科學會會員和美國泌尿外科學會委員等職。梅驊先生曾主持撰 寫三本關於泌尿外科手術的學術專著。

劉力生女士,於二零零五年五月接受邀請成為本集團高級醫藥 學術顧問。劉女士於一九五零年取得北京燕京大學理學學士學 位,一九五四年於北京協和醫學院獲博士學位。期後,劉女士 於一九八一年取得美國伯明翰阿拉巴馬大學心血管研究所博士 學位。劉女士現時為中國醫學科學院北京阜外心血管病醫院教 授、北京高血壓聯盟研究所所長,及中國衛生部心血管病防 治研究中心副主任和亞太高血壓學會主席。自一九八八年起, 劉女士擔任中華心血管病學會主任委員及名譽主任委員,自 一九八九年起,擔任中國高血壓聯盟主席一職;於一九九九 年,並成為世界高血壓聯盟副主席及世界衛生組織發展中國家 心血管病研究執行委員會聯合主席,並於二零零六年被推選為 世界高血壓聯盟主席。劉女士一直擔任《中國高血壓》雜誌主編 及各地有關心血管和高血壓醫學雜誌的編委。

SENIOR MANAGEMENT

Mr. YAO, Shi An, aged 56, is the Vice President of the Company and is responsible for the Group's development projects on research and external cooperation and manufacturing facilities construction planning. Mr. Yao graduated from Beijing Technology and Business University and has accumulated over thirty years of technical and corporate management experience in the chemical and pharmaceutical industries in the PRC. Mr. Yao was an executive director and the executive president of China Pharmaceutical Group Limited, a company listed on the Stock Exchange, before joining the Group in July 2006.

Mr. LAM, Kam Wah, aged 53, is the Vice President of the Company. Mr. Lam also holds directorship in Suzhou Dawnrays Pharmaceutical Co., Ltd., Suzhou Dawnrays Chemical Co., Ltd. and Dawnrays Pharma (Hong Kong) Ltd., which are all subsidiaries of the Company. He graduated from The Chinese University of Hong Kong with a Bachelor degree in Social Sciences. Mr. Lam joined the Group in December 1995 and he has over fifteen years of experience in pharmaceutical trading and corporate management. Mr. Lam is responsible for the international business of the Group and the daily administration of the Company.

Mr. ZHU, Qin Sheng, aged 54, is the Vice President of the Company, responsible for assisting the Chief Executive Officer in the aspects of production and sales, production planning, logistic management, safety and environmental protection. Mr. Zhu has over twenty-five years' experience in production management, financial management and operations for pharmaceutical enterprises. He was the deputy factory director of 蘇州第三製蔡廠 (Suzhou Third Pharmaceutical Factory) before joining the Group in April 1998.

Ms. WU, Ji Hong, aged 36, is the Financial Controller of the Group. Ms. Wu is responsible for the Group's financial planning, capital budgeting, execution of the Group's costing, budget planning and execution, finance & accounting department management and other financial operations. Ms. Wu obtained a Bachelor degree of Science from The Economics and Commercial Institution of Center-South University with major in Economics and attained Chinese Certified Public Accountants (Level two). Ms. Wu has over ten years' experience in auditing, budgeting, financial management, corporate banking, taxation, PRC's taxation regulations and company law. Ms. Wu joined the Group in July 2003.

Mr. BO, Hui, aged 45, is the Head of Sales and Marketing of the Group. Mr. Bo graduated from the School of Pharmacy of Shengyang Pharmaceutical University with a Bachelor degree in Pharmacy and the Postgraduate program in Medical Economics from the National Sun Yat-sen University. Mr. Bo specializes in pharmacology and has accumulated over 20 years experience in pharmaceutical sales, marketing and business development. Mr. Bo was the general manager of Livzon Pharmaceutical Sales Company and the deputy head of sales and marketing of Livzon Pharmaceutical Group Inc. Mr. Bo joined the Group in August 2004.

Mr. CHEN, Jian Dong, aged 42, is the Head of Research and Development of the Group. Mr. Chen was the general manager of former Suzhou Dawnrays Pharmaceutical Technology Co., Ltd. Mr. Chen is a qualified pharmaceutical engineer and licensed pharmacist and has a Bachelor degree in Chemical Pharmacology from 中國 蔡科大學 (The Pharmaceuticals University of the PRC) where he spent three years as an assistant teacher. He was the head of the research centre and antibiotics workshop manager at 蘇州第四製藥廠 (Suzhou Fourth Pharmaceutical Factory) and the head of the registration section of the research and development department of 蘇州中化藥品工業有限公司 (Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd.) before joining the Group in April 2002.

高級管理層

姚世安先生,56歲,本公司副總裁,負責本集團的科研、對外 合作項目開發,及基建等工作。姚先生畢業於北京工商大學, 在中國的化學和製藥行業擁有超過三十年的技術和企業管理經 驗。於二零零六年七月加盟本集團前,姚先生擔任中國製藥集 團有限公司(一間於聯交所上市的公司)之執行董事及執行總 裁。

林錦華先生,53歲,本公司副總裁。林先生亦於本公司之附屬 公司包括蘇州東瑞製藥有限公司、蘇州東瑞化工有限公司及東 瑞葯業(香港)有限公司擔任董事職務。林先生畢業於香港中文 大學,持有社會科學學士學位。林先生於一九九五年十二月加 盟本集團,他在醫藥貿易及管理方面擁有逾十五年經驗,負責 管理本集團國際業務及本公司的日常行政工作。

朱琴生先生,54歲,本公司副總裁,負責協助總裁在集團上 的產銷銜接、生產計劃安排、物流管理、安全及環保等方面工 作。朱先生在製藥企業的生產管理、財務管理及營運方面擁有 超過二十五年經驗。於一九九八年四月加盟本集團前,朱先生 為蘇州第三製藥廠的副廠長。

吴繼紅女士,36歲,本集團財務總監,負責本集團的財務策 劃、資金規劃、成本核算、預算編製及監督、財務部門建設等 財務管理工作。吳女士畢業於中南大學經貿學院,主修經濟 學,持有理學士學位和中國中級會計師資格證書。吳女士於審 計、財政預算、財務管理、銀行信貸、税收、及中國税務法規 及公司法方面擁有超過十年經驗。吳女士於二零零三年七月加 盟本集團。

薄輝先生,45歲,本集團營銷總監。薄先生於瀋陽藥科大學 (瀋陽藥學院)藥學系取得學士學位,並在中山大學管理學院醫 藥經濟研究生畢業。薄先生具有豐富的藥學知識,並在醫藥銷 售、市場推廣及業務發展方面,累計逾二十年經驗。薄先生曾 擔任麗珠醫藥營銷有限公司總經理、麗珠醫藥集團股份有限公 司營銷副總監等管理職位。薄先生於二零零四年八月加盟本集 團。

陳建東先生,42歲,本集團研發總監。陳先生曾擔任本集團原 蘇州東瑞藥物技術有限公司總經理。陳先生為製藥工程師及註 冊藥劑師,自中國藥科大學取得化學藥劑學士學位,並於該大 學擔任助理導師三年。於二零零二年四月加盟本集團前,陳先 生曾任蘇州第四製藥廠研究中心的主管及抗生素車間的經理, 並曾任蘇州中化藥品工業有限公司研究及開發部門註冊部的主 管。

Directors' and Senior Management's Biographies 董事及高級管理層履歷



Mr. SU, Guo Qiang, aged 37, is the General Manager of Suzhou Dawnrays Pharmaceutical Co., Ltd., responsible for the overall operations of Suzhou Dawnrays Pharmaceutical Co., Ltd. Mr. Su graduated from 武漢化工學院 (Wuhan Institute of Chemical Technology) in biopharmaceutical profession and qualified as a pharmaceutical engineer. He was the chief engineer and the head of the research centre of 蘇州第二製藥廠 (Suzhou Second Pharmaceutical Factory). He joined the Group in November 2001.

Mr. LI, Jian Xiang, aged 51, is the General Manager of Suzhou Dawnrays Chemical Co., Ltd., responsible for the overall operations of Suzhou Dawnrays Chemical Co., Ltd. Mr. Li has over twenty-five years' experience in production management, engine facilities maintenance and operations for pharmaceutical enterprises. He was the factory director of 蘇州第二製藥廠 (Suzhou Second Pharmaceutical Factory) before joining the Group in April 1998.

Mr. SHAO, Jian Liang, aged 43, is the General Manager of the Shanghai Dawnrays Chemical Co., Ltd., responsible for the overall operations of Shanghai Dawnrays Chemical Co., Ltd. Mr. Shao graduated from 江蘇廣播電視大學 (Jiangsu Radio and TV University) in fine organic chemical engineering. He joined the Group in June 1997 and was the bulk medicine workshop manager of Suzhou Dawnrays Pharmaceutical Co., Ltd. and the deputy general manager of Shanghai Dawnrays Chemical Co., Ltd.

Mr. KWONG, Chak Lam, aged 38, is the Qualified Accountant of the Company. He is a member of the Hong Kong Institute of Certified Public Accountants and The Association of Chartered Certified Accountants. Mr. Kwong has over ten years' experience in accounting. He joined the Group in July 2005. 蘇國強先生,37歲,蘇州東瑞製藥有限公司總經理,負責蘇 州東瑞製藥有限公司的整體營運工作。蘇先生畢業於武漢化工 學院化學製藥專業,為製藥工程師,曾任蘇州第二製藥廠研究 所所長,總工程師等職。蘇先生於二零零一年十一月加盟本集 團。

李建翔先生,51歲,蘇州東瑞化工有限公司的總經理,負責 蘇州東瑞化工有限公司的整體營運工作。李先生在製藥企業的 生產管理、機器設施保養及營運方面擁有超過二十五年經驗。 於一九九八年四月加盟本集團前,李先生為蘇州第二製藥廠廠 長。

邵建良先生,43歲,上海東瑞化工有限公司總經理,負責上海 東瑞化工有限公司整體營運工作。邵先生畢業於江蘇廣播電視 大學精細有機化工專業,於一九九七年六月加盟本集團,曾任 蘇州東瑞製藥有限公司原料藥車間主管及上海東瑞化工有限公 司常務副總經理。

鄺澤霖先生,38歲,本公司合資格會計師。鄺先生是香港會計 師公會及英國特許會計師公會會員。鄺先生於會計工作方面擁 有逾十年經驗。鄺先生於二零零五年七月加盟本集團。